ロード中...
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses characterized the population pharmacokinetics of upa...
保存先:
| 出版年: | Clin Pharmacokinet |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6614152/ https://ncbi.nlm.nih.gov/pubmed/30945116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00739-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|